Raloxifene Hydrochloride Tablet, Film Coated
Product Images NDC 50228-306

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 50228-306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label – Raloxifene, 60mg Bottle, 30ct (60 mg 2000tab)

Label for Raloxifene Hydrochloride Tablets USP, 60 mg, film-coated oral tablets. The label includes dosage instructions, storage conditions, and a note to dispense the Medication Guide to each patient. It shows a package size of 2,000 tablets, marked Rx only, and is manufactured by ScieGen Pharmaceuticals Inc, Hauppauge, NY. The NDC is 50228-306-20.*

FDA Label Image

Package Label – Raloxifene, 60mg Bottle, 30ct (60 mg 30tab)

Label for Raloxifene Hydrochloride Tablets, USP 60 mg, manufactured by ScieGen Pharmaceuticals Inc. The film-coated oral tablets are available in a package of 30. The label includes storage instructions, pharmacist dispensing guidance, and a barcode with NDC 50228-306-30.*

FDA Label Image

Chemical Structure (Raloxifene Pi 01v1)

Chemical structure of raloxifene hydrochloride showing the molecular arrangement including phenyl rings, hydroxyl groups, a thiophene ring, and a piperidine moiety with chloride ion (Cl-) indicated.*

FDA Label Image

Figure 1 (Raloxifene Pi 02v1)

Two line graphs showing total hip mean percentage change from baseline over 24 months after randomization. The top graph compares Raloxifene hydrochloride and placebo in studies NA and EU, illustrating Raloxifene's positive percentage change and placebo's slight negative change. The bottom graph includes Raloxifene hydrochloride, placebo, and conjugated estrogens (CE) in hypertomized women, showing CE with the highest increase, followed by Raloxifene, and placebo decreasing over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.